Adjuvant pembrolizumab after nephrectomy stands as the current standard of care for clear cell renal cell carcinoma patients at increased recurrence risk, according to clinical guidelines, yet the field navigates divergent phase III trial results and a lack of validated predictive biomarkers. Medical professionals continue to debate risk stratification models, significant treatment toxicities, and management strategies for patients who experience recurrence after immunotherapy.
Renal Cell Carcinoma Recurrence Risk and Stratification Models
An estimated 80,450 new kidney cancer diagnoses and 15,160 deaths are expected in the United States, with renal cell carcinoma accounting for roughly 90% of cases, according to American Cancer Society data. While surgery cures the majority of patients with localized disease, recurrence strikes up to 40% of individuals with higher-stage or higher-grade tumors, as noted by Furukawa et al. Clinicians utilize several clinicopathological models to gauge this danger, including the Leibovich score, which incorporates tumor stage, lymph node status, tumor size, nuclear grade, and necrosis. According to Leibovich et al., this score yields five-year metastasis-free survival rates of approximately 97% for low-risk patients, 74% for intermediate-risk cases, and 31% for high-risk individuals. Additional prognostic insights come from the UISS and SSIGN scores, as outlined by Patard et al. Meanwhile, the KEYNOTE-564 TNM-based risk strata serve as the preferred classification for operable clear cell renal cell carcinoma, categorizing intermediate-high risk as pT2 grade 4 or sarcomatoid N0M0 or pT3 any grade N0M0, and high risk as pT4 any grade N0M0 or any pT N+M0, alongside M1 NED after complete metastasectomy, according to Powles et al.
Phase III Adjuvant Trial Evidence and Divergent Outcomes
Five phase III trials have evaluated adjuvant immune checkpoint inhibitors in renal cell carcinoma, though only KEYNOTE-564 has demonstrated both disease-free survival and overall survival benefit. KEYNOTE-564 evaluated adjuvant pembrolizumab against a placebo in 994 patients, showing a 48-month overall survival rate of 91.2% versus 86.0% at a median follow-up of 57.2 months, according to Haas et al. Conversely, the IMmotion010 trial evaluated adjuvant atezolizumab versus placebo in 778 patients and failed its primary endpoint, with a median disease-free survival of 57.2 months versus 49.5 months, according to Pal et al. Similarly, the CheckMate 914 trial found that nivolumab plus ipilimumab and nivolumab monotherapy did not improve disease-free survival compared to placebo, according to Motzer et al. The PROSPER trial tested a perioperative approach using neoadjuvant and adjuvant nivolumab and was stopped for futility after reporting a recurrence-free survival hazard ratio of 0.94, according to Allaf et al. More recently, the RAMPART trial utilized the Leibovich score, with James M. Larkin presenting results at the ASCO Annual Meeting showing that durvalumab monotherapy did not significantly improve disease-free survival compared with active monitoring, though the combination of durvalumab and tremelimumab improved disease-free survival in the higher-risk subgroup, according to Larkin et al.
Pro Tip: When evaluating adjuvant treatment options for clear cell renal cell carcinoma, clinicians should review individual risk strata rather than relying solely on broad disease categories, as intermediate-high risk populations remain notably heterogeneous.
Evaluating Novel Combinations and Biomarker Limitations
Recent investigations have explored combination therapies alongside the search for reliable prognostic biomarkers. The LITESPARK-022 trial evaluated adjuvant pembrolizumab plus belzutifan, a HIF-2α inhibitor, versus pembrolizumab plus placebo in 1,841 patients, finding a significant improvement in disease-free survival, with a 24-month rate of 80.7% versus 73.7%, according to Choueiri et al. However, overall survival did not differ significantly at the interim analysis. Despite these trial expansions, the field lacks a validated predictive biomarker to guide adjuvant pembrolizumab use, as noted by Buti et al. PD-L1 expression is not predictive in this setting, and testing is not recommended to inform treatment decisions, according to Powles et al. Furthermore, circulating tumor DNA analysis from KEYNOTE-564 presented at the ASCO meeting showed baseline detection in only 5.4% to 8.2% of patients, with a sensitivity of just 10% to 15%, precluding its current use for patient selection, according to Choueiri et al.
Managing Toxicity and Post-Recurrence Treatment Pathways
The toxicity calculus shifts in the adjuvant setting because many patients are already cured by surgery, meaning immune-related adverse events represent harm without compensating benefit. In KEYNOTE-564, immune-mediated adverse events occurred in 36.5% of pembrolizumab recipients compared to 7.3% in the placebo arm, with 21.1% discontinuing treatment due to adverse events, according to Choueiri et al. Permanent endocrinopathies such as hypothyroidism and adrenal insufficiency require lifelong hormone replacement, prompting updated European Association of Urology guidelines to recommend discussing overtreatment risks on a case-by-case basis. When recurrence strikes after adjuvant immunotherapy, a retrospective study of 70 patients reported a 21% recurrence rate, with two-thirds presenting as oligometastatic disease, according to Ciccarese et al. Patients receiving metastasis-directed local therapy achieved a 24-month post-progression survival of 100%, compared to 86% for systemic therapy, and all patients starting systemic treatment received vascular endothelial growth factor receptor tyrosine kinase inhibitor regimens, as immune checkpoint inhibitor rechallenge is not recommended.
Did You Know?
Excess body weight is implicated in 19% of kidney cancer deaths globally, highlighting lifestyle and metabolic factors alongside genetic and surgical considerations in renal health, according to the World Health Organization 2026 Global Cancer Report.
Frequently Asked Questions
What is the current standard of care for clear cell renal cell carcinoma at increased risk of recurrence?
Adjuvant pembrolizumab after nephrectomy is the established standard of care for patients with clear cell renal cell carcinoma at increased risk of recurrence, according to clinical trial evidence and consensus guidelines.
Do circulating tumor DNA assays currently guide adjuvant therapy decisions in renal cell carcinoma?
No, circulating tumor DNA assays are not currently used for patient selection because baseline detection rates remain low and sensitivity for predicting disease-free survival events is limited, according to findings presented by Choueiri et al.
What is the recommended treatment approach when a patient recurs after adjuvant immunotherapy?
When recurrence occurs following adjuvant immunotherapy, patients typically receive vascular endothelial growth factor receptor tyrosine kinase inhibitor regimens, as immediate immune checkpoint inhibitor rechallenge is not recommended, according to Ciccarese et al.
How do side effects impact adjuvant immunotherapy decisions?
Immune-mediated adverse events and permanent endocrinopathies like hypothyroidism affect a substantial minority of patients, requiring clinicians to weigh potential recurrence reduction against the risk of treating individuals who may already be cured by surgery alone.
How to navigate risk stratification, trial discrepancies, and real-world toxicities will take center stage at the Community Oncology Global Congress 2026, an international virtual event scheduled for 28–30 August 2026. Explore more cancer care insights and expert discussions by subscribing to updates and visiting OncoDaily YouTube TV.
Worth a look